Skip to search formSkip to main contentSkip to account menu

CP 358774

Known as: CP-358774, Cp-358,774, 358,774, CP 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Erlotinib Hydrochlorideerlotinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2003
Review
2003
The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
Epidermal growth factor receptor (EGFR) is commonly overexpressed in a number of epithelial malignancies and is often associated… 
Review
2003
Review
2003
Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Erlotinib [Tarceva, R 1415, CP 358774, OSI 774, NSC 718781] is a small molecular, once-a-day, orally active inhibitor of the… 
Review
2003
Review
2003
Second-line chemotherapy for non-small cell lung cancer
Several agents have been evaluated for the second-line treatment of patients with non-small cell lung cancer. The TAX 317 trial… 
Review
2001
Review
2001
OSI-774 OSI Pharmaceuticals.
OSI-774 (formerly CP-358774), a quinazoline derivative, is an orally active epidermal growth factor receptor (EGFR) inhibitor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)